Acute pain is a type of pain that comes on quickly but lasts a short amount of time. Journavx (jor-na-vix) was approved in 2025 and is the first non-opioid medicine in its class that is used to ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

“With the approval of JOURNAVX, a non-opioid ... we have the opportunity to change the paradigm of acute pain management and establish a new standard of care.” The approval is considered ...

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

Journavx was evaluated in two random double ... "We have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Kewalramani said.

The approval of Journavx, a non-opioid pain medication, could provide a safer alternative for pain management.

"By managing acute pain effectively, [Journavx] may help prevent the transition to chronic pain, reducing the need for long-term pain management strategies," he added. The drug cannot be used with ...

Enter: Journavx, the first pain medication of its ... an anesthesiologist and former director of the pain management division at Hospital for Special Surgery in New York. “It appears to be ...

Journavx became the first drug in a new class of pain management medications to be FDA approved. The treatment showed statistically significant superiority to placebo in trials. Perspective from ...